ALS

This study looked at the safety of an oral form of edaravone for people with ALS, a nerve disease that weakens muscles. Fifteen patients who had already been in earlier studies took the drug for 10 days every two weeks. Researchers tracked side effects to see if the treatment was…

This study tested a new drug called PrimeC in 69 people with ALS (Lou Gehrig's disease) to see if it is safe and can slow the disease. Participants took PrimeC or a placebo twice daily for 6 months, and everyone who finished could then receive PrimeC for another 12 months. The go…

This study looked at the long-term safety of an oral form of edaravone in 185 people with ALS. Participants took the medication for 24 to 48 weeks, and researchers tracked any side effects. The goal was to see if taking the drug by mouth is safe over time for managing ALS.

This study tested a new drug called IFB-088 added to the standard ALS medication riluzole in 51 people with bulbar-onset ALS (a form that first affects speech and swallowing). The goal was to see if the combination is safe and shows signs of slowing the disease. Participants rece…

This study looked at whether a moderate intensity breathing exercise program is safe and doable for people with ALS. Nine adults with ALS did four 3-week cycles of respiratory muscle training at home, with weekly check-ins via video call. The main goals were to see if participant…

This study looked at how nerves in the spine work in people with ALS compared to healthy volunteers. The goal was to find specific electrical signals that could help doctors understand the disease better and diagnose it earlier. About 100 people took part, and the results may lea…